Frankfurt
31.10.25 | 15:29
5,700 Euro
-9,52 % -0,600
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Fortress Biotech: Aktie legt zu - Gichtmittel der Tochtergesellschaft erreicht Phase-3-Studie | 4 | Investing.com Deutsch | ||
| 21.10. | Fortress Biotech stock rises after subsidiary's gout treatment enters Phase 3 trials | 2 | Investing.com | ||
| 21.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 159 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 02.10. | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 17 | Investing.com Deutsch | ||
| 02.10. | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 01.10. | Fortress Biotech stock plummets after FDA rejects Menkes disease drug | 13 | Investing.com | ||
| 01.10. | Fortress Biotech plunges as FDA rejects rare disease drug | 12 | Seeking Alpha | ||
| 01.10. | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 86 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 114 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen | |
| 21.08. | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 26 | Investing.com | ||
| 14.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 421 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | 276 | GlobeNewswire (Europe) | MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value... ► Artikel lesen | |
| 15.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 425 | GlobeNewswire (Europe) | Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint... ► Artikel lesen | |
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights | 142 | GlobeNewswire (Europe) | Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary... ► Artikel lesen | |
| 17.03. | Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform | 238 | GlobeNewswire (Europe) | FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 308,30 | -0,29 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 563,00 | -0,49 % | Paradigmenwechsel in der Glaukommedizin? NurExone erzielt dosisabhängige Wiederherstellung des Sehvermögens | ||
| VIKING THERAPEUTICS | 33,185 | +0,51 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| INTELLIA THERAPEUTICS | 11,060 | -0,36 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,50 | +0,64 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| NUREXONE BIOLOGIC | 0,439 | -2,23 % | Disruptive Wissenschaft auf großer Bühne: NurExone qualifiziert sich als Finalist bei Falling Walls Venture 2025 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,972 | -3,09 % | Cathie Wood's ARK ETFs buy DraftKings, Pacific Biosciences stock | ||
| GINKGO BIOWORKS | 11,200 | 0,00 % | Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture | BOSTON, Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| IOVANCE BIOTHERAPEUTICS | 1,675 | -1,66 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,110 | +0,26 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| SANA BIOTECHNOLOGY | 4,945 | +1,33 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| BIOMEA FUSION | 1,370 | +3,40 % | Biomea Fusion, Inc.: Biomea Fusion to Present Poster Presentations at ObesityWeek2025 | ||
| TERNS PHARMACEUTICALS | 7,100 | -1,39 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity | Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Biotech-Boom: Novartis übernimmt Avidity Biosciences für 12 Milliarden US$ | Der Schweizer Pharmakonzern Novartis hat einen bedeutenden Schritt in der Erweiterung seines Portfolios gemacht. Mit der Übernahme des US-Biotechnologieunternehmens Avidity Biosciences stärkt Novartis... ► Artikel lesen |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,600 (-9,52 %) liegt der Kurs bei 5,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.